Ken Griffin Cyclerion Therapeutics, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.58 - $18.2 $6,177 - $193,848	10,651 New	10,651 $9,000
Q4 2021 Feb 14, 2022	BUY	$1.56 - $2.99 $30,810 - $59,052	19,750 Added 26.91%	93,134 $160,000
Q3 2021 Nov 15, 2021	SELL	$2.73 - $4.13 $46,161 - $69,834	-16,909 Reduced 18.73%	73,384 $225,000
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.29 $165,826 - $326,327	76,067 Added 534.7%	90,293 $352,000
Q1 2021 May 17, 2021	BUY	$2.69 - $5.12 $38,267 - $72,837	14,226 New	14,226 $40,000
Q4 2019 Feb 14, 2020	SELL	$1.8 - $13.43 $421,936 - $3.15 Million	-234,409 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$8.12 - $14.54 $520,004 - $931,141	-64,040 Reduced 21.46%	234,409 $2.84 Million
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $2.87 Million - $6.82 Million	298,449 New	298,449 $3.42 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $143M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.